The CVS Earnings Bombshell That Has Investors Scrambling Right Now
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
At a Glance
- Revenue: $105.69 billion (beat consensus of $104.63 billion)
- Adjusted EPS: $1.09 (beat consensus of $1.00)
- GAAP EPS: $2.30 vs. $1.30 prior year (includes $1.9 billion tax benefit from subsidiary bankruptcy)
- Full-Year 2025 Revenue: $402.1 billion, up 7.8%
- Stock Performance: Closed at $75.77 on February 9, down 3.76% year-to-date
Financial Performance Highlights
CVS Health (NYSE: CVS) delivered a solid revenue beat in Q4 2025, though adjusted earnings declined year-over-year despite exceeding Wall Street expectations. The 8.2% revenue increase to $105.69 billion marked the company’s strongest quarterly top-line growth of the year. However, adjusted EPS of $1.09 declined from $1.19 in Q4 2024, pressured by Medicare Part D headwinds from Inflation Reduction Act seasonality changes.
The GAAP EPS figure of $2.30 benefited significantly from a one-time $1.9 billion tax benefit related to the Omnicare subsidiary bankruptcy filing, masking underlying operational challenges.
Segment Performance
Health Care Benefits posted $36.29 billion in revenue (up 10.1%), but its adjusted operating loss widened to $676 million from $439 million the previous year. The segment shed 504,000 members year-over-year.
Health Services generated $51.24 billion in revenue (up 9.0%) with adjusted operating income rising 9.2%. Pharmacy & Consumer Wellness delivered $37.66 billion (up 12.4%), benefiting from Rite Aid prescription file acquisitions.
2026 Guidance
CVS confirmed adjusted EPS guidance of $7.00 to $7.20 for 2026, but reduced operating cash flow expectations to at least $9.0 billion from a prior $10.0 billion target, signaling continued pressure on working capital.
Contact [email protected] for any questions or corrections.








